Patents by Inventor Erik Tucker

Erik Tucker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR SAFELY REDUCING THROMBOPOIETIN
    Publication number: 20210275569
    Abstract: Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual. Such methods, compounds, and compositions maintain platelet count within a safe hemostatic range. Such methods, compounds, and compositions are useful to safely treat, prevent, or ameliorate a disease that can benefit from platelet count reduction in an individual. Such methods, compounds, and compositions are useful for treating or preventing diseases in which thrombopoietin contributes to the presence or activation of platelets contributes to and promotes disease initiation or progression, and/or adversely affects disease outcome.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 9, 2021
    Applicants: Aronora, Inc., Oregon Health & Science University, Ionis Pharmaceuticals, Inc.
    Inventors: Andras Gruber, Erik Tucker, Brett P. Monia, Alexey Revenko
  • Antibodies capable of binding to the coagulation factor XIa and uses thereof
    Patent number: 11046783
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 29, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • Antibodies against factor XI and uses thereof
    Patent number: 10654941
    Abstract: The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 19, 2020
    Assignees: Bayer Pharma Aktiengesellschaft, ARONORA INC.
    Inventors: Andreas Wilmen, Anja Buchmüller, Erik Tucker
  • ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XIA AND USES THEREOF
    Publication number: 20190284300
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 19, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • NOVEL ANTIBODIES AGAINST FACTOR XI AND USES THEREOF
    Publication number: 20190225705
    Abstract: The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.
    Type: Application
    Filed: September 18, 2017
    Publication date: July 25, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, ARONORA INC.
    Inventors: Andreas WILMEN, Anja BUCHMÜLLER, Erik TUCKER
  • Antibodies capable of binding to the coagulation factor XIa and uses thereof
    Patent number: 10221247
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: March 5, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof
    Patent number: 10040866
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 7, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XIA AND USES THEREOF
    Publication number: 20180112009
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: August 30, 2017
    Publication date: April 26, 2018
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • NUCLEIC ACIDS AND HOST CELLS EXPRESSING ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XIA AND USES THEREOF
    Publication number: 20180051093
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: August 30, 2017
    Publication date: February 22, 2018
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
    Patent number: 9783614
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: October 10, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straβburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jöriβen, Asako Itakura, Philberta Leung, Erik Tucker
  • Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and uses thereof
    Publication number: 20150099298
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 9, 2015
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker